Satsuma Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company founded in 2016, with a focus on providing innovative treatments for migraine and other debilitating conditions. Their flagship product candidate, STS101 (dihydroergotamine (DHE) nasal powder), is being developed as a differentiated therapeutic option for the acute treatment of migraine. The company's commitment to addressing unmet medical needs in the biotechnology, health care, and pharmaceutical industries has attracted significant investment interest.
Their most recent milestone was a $80.00M Post-IPO Equity investment on 01 March 2021, which attracted participation from a diverse group of investors including New Enterprise Associates, RA Capital Management, Vivo Capital, Commodore Capital, Logos Capital, Point72, Aspire Capital Partners, LLC, Surveyor Capital, Shin Nippon Biomedical Laboratories (SNBL), and Ghost Tree Capital Group.
With its strong investor backing and a promising product pipeline, Satsuma Pharmaceuticals, Inc. is well-positioned to make a meaningful impact in addressing the needs of patients suffering from migraine and other related conditions.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Post-IPO Equity | $80.00M | 10 |
|
01 Mar 2021 |
| Series B | $62.00M | - | 24 Apr 2019 | |
| Series A | $12.00M | - | 06 Jan 2017 |
No recent news or press coverage available for Satsuma Pharmaceuticals, Inc..
We care about your data, and we'd love to use cookies make your experience better.
